Innate immunity in the Guillain-Barré syndrome

Recruiting

Conditions: acute inflammatory demyelinating polyneuropathy
no lay-term
10034606

Registration Number: NL-OMON45725

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 124

Inclusion Criteria

Healthy controls:
- Age 18 years or older
- Written informed consent given by the subject

Former GBS patients:
- Fulfilling the diagnostic criteria for GBS (Asbury, 1990), or its variant Miller Fisher syndrome (MFS).
- Current age 18 years or older
- Written informed consent given by the patient;Recurrent GBS patients:
- Occurrence of at least two episodes of GBS, as determined by the diagnostic criteria for GBS (Asbury, 1990), or its variant Miller Fisher syndrome (MFS).
- Age 18 years
- Written informed consent given by the patient

Exclusion Criteria

Healthy controls:
- No serological evidence for exposure to a virus, as determined by IgG serology for EBV, CMV, HEV or influenza antigens.;All groups:
Additional diseases or disorders at time of blood sampling that may influence the endpoints:
- autoimmune diseases (like multiple sclerosis, psoriasis, Crohn*s disease, ulcerative colitis, rheumatoid arthritis, SLE and other systemic diseases)
- acute and chronic infectious diseases (like infectious mononucleosis, HIV/AIDS)
- malignancies (not in remission)
Medicines at time of blood sampling that may affect endpoints (i.e. inflammatory processes):
- NSAIDs, oral corticosteroids, cyclosporine
- Cytostatic compounds
- Cytokines (analogues) and biologicals
- Intravenous immunoglobulins.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter is the innate response of leukocytes to microbial<br /><br>triggers as determined by the type I interferon production in response to<br /><br>stimulation of Toll-like receptor 3, 7 or 9. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The production of other cytokines and the expression of maturation/activation<br /><br>markers will be determined at the cell surface of leukocytes. Additionally,<br /><br>genetic variants that influence the innate response of leukocytes to microbial<br /><br>triggers will be determined.</p><br>